Pfizer has ended the global commercialisation of its haemophilia B (factor IX deficiency) gene therapy Beqvez, citing soft demand for gene therapies among haemophilia patients and physicians.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback